Psilocin Crystalline Forms Patent Application

ChangeBridge: Patent Apps - Organic Chemistry (C07D)

Detected March 26th, 2026

Summary

The USPTO has published a patent application (US20260085039A1) detailing crystalline forms of psilocin, including salts and cocrystals. The application, filed by Jim Gilligan and Peter Guzzo, describes these forms as having improved physical properties like aqueous solubility and stability, suitable for various administration routes.

View original document View source feed page

What changed

This document is a publication of a patent application filed with the USPTO, specifically application number US20260085039A1, concerning crystalline forms of psilocin. The application, filed on September 12, 2023, by inventors Jim Gilligan and Peter Guzzo, describes novel crystalline forms of psilocin salts or cocrystals, emphasizing improved aqueous solubility and stability for pharmaceutical use.

As this is a patent application, it does not impose immediate regulatory obligations or compliance deadlines on drug manufacturers. However, it signifies potential future intellectual property claims related to psilocin-based therapeutics. Companies involved in psilocin research or development should monitor the progress of this application and similar filings to understand the evolving patent landscape in this area.

Source document (simplified)

← USPTO Patent Applications

Psilocin crystalline forms

Application US20260085039A1 Kind: A1 Mar 26, 2026

Inventors

Jim GILLIGAN, Peter GUZZO

Abstract

The present invention relates to crystalline forms of psilocin (4-hydroxy-N,N-dimethyltryptamine) salts or cocrystals, as well as compositions, methods of preparation and methods of their use. The present invention also relates to said crystalline forms having improved physical properties such as aqueous solubility and stability, wherein the crystalline forms and compositions thereof are suitable for oral, subcutaneous, intravenous, or intramuscular administration.